Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
May 20, 2024 14:30 ET
|
Korro Bio, Inc.
KRRO-110 showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo genetic Alpha-1 Antitrypsin...
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer
May 14, 2024 16:01 ET
|
Korro Bio, Inc.
On track for regulatory filing for First-in-Human (FIH) study of KRRO-110 in patients with Alpha-1 Antitrypsin Deficiency (AATD) anticipated in the second half of 2024 Further strengthened...
Korro Announces $70 Million Private Placement
April 18, 2024 08:30 ET
|
Korro Bio, Inc.
Financing led by Deep Track Capital with participation from other leading healthcare investors Pro-forma cash and cash equivalents of approximately $236 million before fees and expenses On track for...
Korro to Participate in Upcoming Investor Conferences
April 01, 2024 16:01 ET
|
Korro Bio, Inc.
CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., Chief Financial Officer,...
Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress
March 26, 2024 16:01 ET
|
Korro Bio, Inc.
On track for regulatory filing for First-in-Human study of KRRO-110 in Alpha-1 Antitrypsin Deficiency (AATD) patients anticipated in the second half of 2024Demonstrated the versatility of Korro’s RNA...
Korro to Present at the TD Cowen 44th Annual Health Care Conference
February 27, 2024 08:00 ET
|
Korro Bio, Inc.
CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the TD Cowen...
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
January 18, 2024 08:00 ET
|
Korro Bio, Inc.
KRRO-110 has a potentially best-in-class profile with secretion of ~50µM functional AAT protein after a single dose in a preclinical mouse modelEvidence of greater than 40% editing of SERPINA1 RNA in...
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 04, 2024 08:00 ET
|
Korro Bio, Inc.
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd...
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
December 07, 2023 08:00 ET
|
Korro Bio, Inc.
KRRO-110 is the first RNA editing oligonucleotide candidate from Korro’s proprietary OPERA™ platform Korro has demonstrated the ability to repair the misfolding of the Alpha-1 Antitrypsin (A1AT)...
Korro Bio Appoints Dr. Rachel Meyers to Board of Directors
November 28, 2023 08:00 ET
|
Korro Bio, Inc.
Biotech veteran brings more than two decades of life science experience to Korro’s Board CAMBRIDGE, Mass., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a...